Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 Nov 2014 |
| Articles of Association for Genmab A/S | 13 Nov 2014 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 12 Nov 2014 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 12 Nov 2014 |
| Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma | 10 Nov 2014 |